The Salmonella Vaccine: How It Works and Its Applications

Salmonella vaccines work by priming the immune system to recognize specific surface structures of Salmonella bacteria, most commonly the Vi capsular polysaccharide that coats Salmonella Typhi, the species responsible for typhoid fever. Two licensed typhoid vaccines have been in use for decades, and a newer conjugate version has shifted the landscape by protecting younger children and lasting longer. But the story extends well beyond typhoid: researchers are developing vaccines against the non-typhoidal strains that cause deadly bloodstream infections in sub-Saharan Africa, veterinary scientists use Salmonella vaccines to keep poultry flocks safer, and cancer researchers have repurposed weakened Salmonella as a vehicle to deliver tumor-fighting antigens directly into immune cells.

The Two Classic Typhoid Vaccines

For years, two typhoid vaccines dominated the field. The first is the Vi capsular polysaccharide vaccine, an injectable shot made from the sugar coating that surrounds S. Typhi. The second is Ty21a, a live-attenuated oral vaccine, meaning it contains a weakened form of the bacterium that can colonize the gut briefly without causing disease. Both reduce the risk of typhoid, but they do so by activating different arms of the immune system.

A randomized trial directly comparing the two found that the injectable Vi vaccine triggers a primarily systemic immune response, generating antibodies that circulate in the blood, while the oral Ty21a vaccine stimulates intestinal immunity that more closely resembles what happens during a natural infection.¹ That distinction matters because Salmonella Typhi enters through the gut lining. A vaccine that builds defenses right at that entry point has a theoretical advantage in blocking infection early, though both vaccines provide meaningful protection in practice.

Each vaccine also has practical trade-offs. The Vi polysaccharide shot requires a single injection but needs a booster every two to three years, and it does not work well in children under two because their immature immune systems struggle to mount strong responses to plain polysaccharide antigens. The Ty21a oral vaccine requires three or four doses taken on alternate days, which complicates delivery in resource-limited settings. Neither vaccine is ideal for the populations that need protection most: young children in typhoid-endemic regions of South and Southeast Asia and sub-Saharan Africa.

Conjugate Vaccines Changed the Game

The limitations of the older vaccines drove the development of typhoid conjugate vaccines, which link the Vi polysaccharide to a carrier protein. This chemical coupling transforms the immune response: instead of just making antibodies that fade quickly, the vaccine recruits a broader set of immune cells, produces longer-lasting memory, and works in infants and toddlers whose immune systems respond poorly to polysaccharides alone.

The most advanced of these is Typbar-TCV, which conjugates the Vi polysaccharide to tetanus toxoid. In a phase 3 trial, Typbar-TCV generated antibody levels roughly three times higher than the older Vi polysaccharide vaccine six weeks after vaccination, with stronger antibody quality (measured by how tightly the antibodies bind their target) persisting at two years.² No serious vaccine-related side effects were reported across infants, children, and adults in that trial.

Follow-up data has been striking. Among children vaccinated before age two, antibody levels remained five-fold above baseline even seven years later without a booster, and virtually all of these children still exceeded what researchers consider a protective threshold at that time point.³ Children who received a booster dose maintained even higher levels, with about 71% showing seroconversion at the seven-year mark compared to 44% of those who went unboosted. These are reassuring numbers for a single-dose vaccine aimed at mass campaigns.

A large phase 3 trial in Malawi confirmed that the real-world protection matches the immune data. A single dose of the Vi-tetanus toxoid conjugate vaccine was durably effective for at least four years in children aged nine months to twelve years, including those vaccinated before their second birthday.⁴ The World Health Organization now recommends mass vaccination campaigns for children aged nine months to fifteen years in endemic areas, followed by routine immunization in the first two years of life.

How Salmonella Vaccines Train the Immune System

The immune response to Salmonella is unusually layered, which is part of why vaccine design has been challenging. Salmonella doesn’t just sit in the gut or float around in the bloodstream; it actively invades immune cells called macrophages and survives inside them. Clearing the infection requires more than just antibodies. The body also needs a robust cell-mediated response, where specialized T cells detect and destroy infected cells from within.

Animal studies established early on that both CD4+ and CD8+ T cells, along with signaling molecules like interferon-gamma and tumor necrosis factor-alpha, are critical for recalling immunity after vaccination with live-attenuated Salmonella strains. When researchers depleted these immune components in vaccinated mice, the animals lost their ability to fight off a subsequent challenge with virulent Salmonella, showing higher bacterial loads and increased mortality.⁵

This is why the route of vaccine delivery matters so much. Oral vaccines like Ty21a are delivered through the gut, which allows them to interact with the mucosal immune system at the very site where Salmonella normally invades. Researchers have argued that topical gastrointestinal delivery could improve vaccine efficacy by stimulating local defenses, including secretory antibodies and tissue-resident immune cells that patrol the intestinal lining.⁶ Injectable vaccines, by contrast, are better at generating circulating antibodies that prevent bacteria from spreading through the bloodstream once an infection has already breached the gut wall. The ideal Salmonella vaccine would do both.

Testing Vaccines in Controlled Human Infection Models

One tool that has accelerated typhoid vaccine development is the controlled human infection model, in which healthy volunteers deliberately swallow a calibrated dose of Salmonella Typhi in a clinical setting. These studies let researchers measure how well a vaccine prevents infection under tightly controlled conditions, without waiting years for large field trials to accumulate enough natural cases.

A landmark challenge study tested two candidates against placebo: the live-attenuated vaccine M01ZH09 (a single oral dose) and the established Ty21a (given as three doses). Neither vaccine achieved dramatic overall protection in this particular trial, but both significantly reduced the bacterial burden in volunteers who did become infected and altered the clinical profile of disease. When the analysis accounted for participants’ baseline antibody levels, the single-dose M01ZH09 showed significant protection against developing typhoid fever.⁷ These models have been instrumental in refining vaccine candidates before they enter expensive large-scale efficacy trials.⁸

Non-Typhoidal Salmonella and the Vaccine Gap

Typhoid gets the headlines, but invasive non-typhoidal Salmonella (iNTS) disease is a quieter crisis. In sub-Saharan Africa, strains like Salmonella Typhimurium and Salmonella Enteritidis cause bloodstream infections that kill tens of thousands of people annually, with death rates particularly high among young children, people living with HIV, and those with malaria or malnutrition. Multidrug-resistant strains are increasingly common, and no vaccine is currently licensed against iNTS.⁹

The development pipeline has been gaining momentum, though. The first iNTS vaccine candidate to enter clinical trials in more than fifteen years began testing in 2019, and as of recently, three additional candidates have entered clinical development, with two in phase 2 trials and one in a phase 1/2 study.¹⁰ Some of these candidates combine iNTS antigens with typhoid or paratyphoid components to create broader-coverage vaccines, which would be especially practical in regions where both diseases circulate.

One promising approach uses Generalized Modules for Membrane Antigens, or GMMA, which are essentially nanoscale blebs of the bacterial outer membrane. These particles naturally display the surface sugars (O-antigens) that the immune system uses to identify Salmonella, and they are cheap to produce. In preclinical comparisons, bivalent GMMA vaccines targeting both S. Typhimurium and S. Enteritidis performed comparably to traditional glycoconjugate vaccines, inducing functional antibodies and reducing bacterial loads, but at a fraction of the manufacturing cost.¹¹ For diseases concentrated in low-income countries, affordability is not a minor detail; it often determines whether a vaccine reaches anyone at all.

Another avenue being explored is conjugation chemistry similar to what made Typbar-TCV successful for typhoid. Researchers have conjugated the O-specific polysaccharides of S. Typhimurium and S. Enteritidis to carrier proteins like diphtheria toxoid, which significantly boosted the antibody response compared to unconjugated antigens.⁹ The goal is a trivalent vaccine covering typhoid and the two major iNTS serovars in a single shot.

Poultry Vaccines and Food Safety

Salmonella vaccination is not only a human health concern. Poultry are a major reservoir of Salmonella, and contaminated eggs and meat are a leading source of foodborne salmonellosis worldwide. Vaccinating chickens does not just protect the birds; it reduces the amount of Salmonella entering the food supply.

The poultry vaccine landscape includes live-attenuated strains, killed whole-cell preparations, subunit vaccines, and newer “ghost” vaccines (bacterial cells whose contents have been emptied out, leaving the outer shell intact as an immune target). Each type has trade-offs between strength of immune stimulation, safety in the flock, and compatibility with food-safety testing that needs to distinguish vaccinated birds from infected ones.¹² A systematic review across animal hosts found that ghost vaccine candidates demonstrated the highest efficacy (around 91%) among the various platforms tested, followed by reverse-vaccinology-designed vaccines.

One persistent challenge in veterinary Salmonella vaccination is the so-called DIVA problem: Differentiating Infected from Vaccinated Animals. When regulators test poultry flocks for Salmonella, a positive result from a vaccinated bird using a live-attenuated strain can be indistinguishable from a genuine infection unless the vaccine is specifically designed to leave a diagnostic gap. This has pushed development toward killed and subunit vaccines in some regulatory environments, even when live vaccines may offer stronger gut-level protection.

Salmonella as a Cancer Vaccine Platform

In one of the more creative turns in vaccinology, researchers have repurposed weakened Salmonella strains not to fight Salmonella itself, but to deliver cancer-fighting molecules. The logic is elegant: Salmonella naturally invades macrophages and dendritic cells, the very immune cells responsible for activating anti-tumor responses. If you engineer the bacterium to carry a tumor-associated antigen, Salmonella essentially becomes a Trojan horse that deposits the antigen directly inside the immune cell’s processing machinery.

A team developed an oral cancer vaccine platform using attenuated Salmonella equipped with the bacterium’s Type III Secretion System, a molecular syringe that Salmonella normally uses to inject its own proteins into host cells. By swapping in tumor-associated antigens, researchers were able to deliver those antigens into the cytosol of antigen-presenting cells, triggering the generation of tumor-specific killer T cells.¹³ The system exploits a set of genes (from the SPI2 locus) that Salmonella activates only once it is already inside a macrophage or dendritic cell, ensuring the antigen payload is released in exactly the right place. This work remains preclinical, but it illustrates how deeply Salmonella’s biology has been dissected and re-engineered for purposes far beyond its original disease.

Public Health Impact and Cost-Effectiveness

Vaccines only matter if they reach the people who need them, and for typhoid conjugate vaccines the economic case is strong. Modeling across Gavi-eligible countries (the poorest nations that qualify for subsidized vaccine procurement) projected that routine vaccination alone could avert about 33 million typhoid cases over ten years, representing roughly a 30% drop in incidence. Adding a catch-up campaign for children under fifteen could push that number to around 63 million cases averted.¹⁴

A comparison of multiple economic models found that routine vaccination with or without a catch-up campaign was consistently cost-effective, with costs ranging from roughly $95 to $789 per disability-adjusted life year averted depending on the model and setting.¹⁵ For context, interventions below a country’s per-capita GDP per DALY averted are generally considered cost-effective by global health benchmarks, and these figures fall well under that bar in virtually every endemic country.

Country-specific analyses paint a similar picture. In Bangladesh, the most favorable strategy was nationwide introduction at nine to twelve months of age with a single catch-up campaign for ages one to fifteen. Over ten years, this approach was projected to avert roughly 3.8 million cases and about 11,000 deaths while saving over $170 million compared to no vaccination, making it not just cost-effective but cost-saving.¹⁶

Timing matters enormously during outbreaks. An analysis of the 2015 Kampala typhoid outbreak found that vaccinating early in the epidemic at 70% coverage could have averted over 7,000 cases and 180 deaths, at a cost of roughly $464 per DALY averted, well within the threshold for highly cost-effective interventions.¹⁷ Even at lower coverage levels, early deployment dramatically outperformed delayed action.

The Drug-Resistance Connection

Typhoid vaccination is increasingly discussed in the context of antimicrobial resistance. Drug-resistant typhoid strains, including extensively drug-resistant (XDR) strains that respond to almost no first-line antibiotics, have spread across South Asia and parts of Africa. Vaccination reduces the total number of typhoid cases and, with them, the absolute number of drug-resistant infections. A modeling study found that higher vaccination coverage decreased both sensitive and resistant cases in roughly equal proportion, meaning the fraction of cases caused by resistant strains stayed around 35% regardless of how many people were vaccinated.¹⁸

In other words, vaccination does not preferentially weed out drug-sensitive infections and leave resistant ones standing. It suppresses transmission across the board. Every case prevented, whether caused by a resistant or sensitive strain, is one fewer patient needing antibiotics and one fewer opportunity for resistance to amplify and spread. For health systems already struggling with limited antibiotic options, this indirect benefit may ultimately rival the direct protection against typhoid itself.

Cross-Serotype Protection and the Search for Broader Vaccines

One frustration in Salmonella vaccinology is that the bacterium comes in over 2,500 serovars, and vaccines built around one serovar’s surface sugars do not necessarily protect against others. Existing subunit vaccines against Salmonella provide limited cross-serotype protection, which has motivated the search for conserved antigens, proteins shared across multiple Salmonella serovars that could form the basis of a broader vaccine.¹⁹ Researchers have evaluated several outer membrane proteins and secretion system components as potential universal targets, though this work is still in the early stages of animal testing.

Regulatory hurdles add another layer of complexity. For live-attenuated Salmonella vaccines, agencies like the FDA require at least two independently attenuating mutations in the vaccine strain to ensure it cannot revert to a virulent form. The choice of parent strain also influences how effective the final vaccine is, and strains that perform well in one animal model do not always translate to humans. mRNA-based approaches have also entered the picture, with researchers using computational tools to design Salmonella-specific mRNA constructs targeting outer membrane proteins.²⁰ These are still at the computer-modeling stage, but they represent the kind of platform flexibility that COVID-era vaccine development proved could be moved quickly from design to clinic when the need arises.

Another underappreciated variable is the gut microbiome. The composition of a person’s intestinal bacteria may influence how well they respond to oral Salmonella vaccines, since the microbiome shapes the local immune environment that the vaccine encounters. If two people have substantially different gut flora, they could mount very different immune responses to the same vaccine dose. This is an area where the science is still catching up to the intuition, but it may partly explain why oral vaccines sometimes perform differently in high-income and low-income settings, where diets, hygiene exposures, and microbiome compositions diverge considerably.